MyMD Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed lower by over 1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Pre-IPO Offer: Get A Piece Of A Nearly $5T Global Opportunity By Joining BOXABL As An Early Shareholder At Just $0.80/Share

Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.

Share Price: $0.80

Min. Investment: $1,000

Valuation: $3.5B

CommScope Holding

The Trade: CommScope Holding Company, Inc. COMM Director Claudius Watts IV acquired a total of 10,000 shares an average price of $3.43. To acquire these shares, it cost around $34,264.
What’s Happening: CommScope Holding announced it launched its SYSTIMAX Constellation edge-based platform.
What CommScope Holding Does: CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center and entertainment networks.

LQR House

The Trade: LQR House Inc. LQR CEO Sean Dollinger acquired a total of 86,400 shares at an average price of $1.16. The insider spent around $100,288.
What’s Happening: LQR House reported the pricing of its initial public offering of 1,000,000 shares of common stock at a public offering price of $5.00 per share.
What LQR Does: LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space.

MyMD Pharmaceuticals

The Trade: MyMD Pharmaceuticals, Inc. MYMD Chief Legal Officer Paul Rivard acquired a total of 150,000 shares at an average price of $1.11. To acquire these shares, it cost around $166,500.
What’s Happening: The FDA accepted MyMD Pharmaceuticals' investigational new drug application for Phase 2 study of oral TNF-α inhibitor MYMD-1 in rheumatoid arthritis.
What MyMD Pharmaceuticals Does: MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms.